Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers World Congress 2018

Steven Pirie-Shepherd's Biography



Steven Pirie-Shepherd, Director, Pfizer

Steven Pirie-Shepherd earned his PhD at Edinburgh University and completed postdoctoral work at Duke University and Brandeis University. He then trained in angiogenesis research with Judah Folkman at Harvard University. He transitioning to Industry, where he has been for the last 17 years, engaged in oncology drug discovery and development. For the last 7 years he has been occupied mostly with translational oncology and Biomarker research.

Steven Pirie-Shepherd Image

Development of Target Expression Assays in NSCLC Tumors and the CTC Compartment

Thursday, 29 March 2018 at 15:30

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

Circulating tumor cells (CTCs) are a common focus of research, in part due to their relatively simple and non-invasive means of collection and their potential utility as biomarkers in cancer.  They may also be studied to help further understand the metastatic process. In this presentation, we discuss development of an IHC assay to detect target expression in NSCLC tumors and an immunofluorescence assay to detect target expression in CTCs.  We used these assays to profile matched samples obtained from treatment na├»ve NSCLC patients. We present data characterizing CTC enumeration as well as the detection and relative expression of target in CTCs and tumors from NSCLC patients and discuss the correlations between the presence of the target in CTCs and matched tumor resections.


Add to Calendar ▼2018-03-28 00:00:002018-03-29 00:00:00Europe/LondonCirculating Biomarkers World Congress 2018Circulating Biomarkers World Congress 2018 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com